Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow, some weak ass traders in here....
What time we headed to .01?
They are loading up at .18, pressure building. Surprised the chart guys aren’t all over this yet... once it breaks north they will show up.
Ascending triangle breakout today?
He is a legend....
Some of us already forgot about it.....
Dude, it is clearly stated that they estimated needing $9 mil to complete the trials. Now they have it....260 mil OS is freaking awesome when you have the science to go along with it.
Here she goes
Premarket buys already took out the ask...
Psyched: The First Psychedelics ETF, Beckley Raises $19M, 3 Companies Go Public
1/1/21, 10:49 AM
January 1, 2021 10:49 AM ET (BZ Newswire) -- Cannabis
The Psychedelics Sector Might Soon Get Its First ETF
Financial services company Horizons ETFs Management filed documents with the Ontario Securities Commission for a psychedelics ETF, which is expected to go live on Jan. 15.
The ‘Horizons Psychedelic Stock Index ETF’ would become the first ETF offering dedicated exposure to the psychedelics sector.
The firm, which manages the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) (OTC:HMLSF) among over 93 separate ETFs, has yet to make a public announcement on the launch.
Psilocybin Alpha published a review of the filings, which state that the ETF intends to invest in companies from the psychedelics industry engaged in legal activities with psychedelic drugs.
The ETF is expected to list under the symbol ‘PSYK’ on Canada’s NEO Exchange. It will be a passive ETF, following the North American Psychedelic Stock Index from Solactive, a German financial indices provider.
Beckley Psytech Raises $19M For 5-MeO-DMT Research
Beckley Psytech, the for-profit arm of the Beckley Foundation, raised £14 million (approximately US$19 million) in equity funding.
The proceeds will be used in part to finance a drug development pipeline for 5-MeO-DMT, a psychedelic compound naturally produced by the Sonoran Desert Toad, which has chemical similarities to DMT. The company is in preparations to commence clinical trials on 5-MeO-DMT, according to Business Leader.
The Beckley Foundation is a UK-based think tank and UN-accredited NGO that has been leading research on psychedelics since the late 1990s.
The organization, led by Amanda Feilding, Countess of Wemyss, developed a for profit branch in 2019 in order to navigate the expensive business of clinical research.
The company raised £3 million in May of 2020. This round’s new investors include Noetic Psychedelic Fund LP, a venture fund focused on psychedelics, and Bail Capital.
3 New Psychedelics Companies Go Public
Three companies recently announced go-public dates, adding to the more than 20 psychedelics companies that hit the public markets in 2020.
Mindset Pharma began listing in the Canadian Securities Exchange on Dec. 23 under the symbol ‘MSET.’ The Toronto-based company is putting together a library of intellectual property on psychedelic compounds designed to address chronic neuro-psychiatric disorders.
The company has already synthesized 50 compounds and filed 4 patents on novel chemical structures and synthesis processes.
NeonMind Biosciences, a partially-owned subsidiary of Better Plant Sciences (CSE:PLNT) (OTCQB:VEGGF), announced that it has received approval to list on the CSE on Jan. 4, under the symbol ‘NEON.’
Better Plant owns over 33 million common shares in NeonMind. In November 2020, NeonMind received Health Canada approval to begin pre-clinical trials on the use of psilocybin for food cravings in the context of obesity. The company has also launched a line of non-psychedelic functional mushroom dietary supplements.
Novamind, a Toronto-based mental health company focused on providing access to legal psychedelic therapies, is going public on the CSE on Jan. 5 under the symbol ‘NM.’
The company is developing a three tier business plan through a network of psychedelics-assisted therapy clinics, psychedelics retreats and a clinical research division, focused on providing research infrastructure to other companies in and outside the sector.
The Milestone Round
Psyched Wellness (CSE:PSYC) (OTCQB:DCNPF) announced the launch of its pre-clinical trials on Amanita Muscaria, a type of legal psychoactive mushroom. The first section of the study will focus on analyzing the mushroom’s maximum tolerated dose. On Wednesday, the company also announced starting research on Muscimol, Amanita’s main psychoactive ingredient, for various psychiatric conditions.
Core One Labs (CSE:COOL), (OTC:CLABF) announced the purchase of Vocan Biotechnologies, a Canadian-based genetic engineering and biosynthesis research firm, through an all-stock transaction. Vocan is developing a proprietary production method to biosynthesize psilocybin.
Revive Therapeutics (CSE:RVV) (OTC:RVVTF) announced a letter of intent to acquire full rights to PharmaTher’s intellectual property on psilocybin. These include PharmaTher’s pre-clinical research into traumatic brain injury and stroke, and provisional patent applications on the use of psilocybin for various ailments.
PharmaTher is a wholly-owned subsidiary of Newscope Capital Corporation (OTC:PHRRF).
Copyright © 2021 Benzinga (BZ Newswire, http://www.benzinga.com/licensing). Benzinga does not provide investmentadvice. All rights reserved. Write to editorial@benzinga.com with any questions about this content. Subscribe to Benzinga Pro (http://pro.benzinga.com).
Yep... huge Reiko. I encourage everyone to listen to this. He’s aware of the phase III trial and is excited about the results and knows the history of the drug as well. Thanks for posting the link also.
Let her rip tater chip
HNY dude...
Breaking out now boys....RVVTF
Ha! Very nice! Good to hear all the positive things about this drug from so many sources.
Don’t miss this, big news coming to RVVTF soon. Multi dollar coming.
RVVTF looks to be a strong close here in anticipation of FDA phase III approval soon.
Mm desperation setting in, they were able to get a few to sell down here... looks like chase time into the close...
Yep, just 10 days ago Dr Drew was talking about it on his radio show...google it and listen to the audio.
“Adam and Dr. Drew open the show discussing some of the recent craziness out of Los Angeles mayor Eric Garcetti and his decisions surrounding all electric aircrafts. They then turn to the phones and speak with a caller who wants to discuss organizations that are uniting ‘non cowards’ around the nation. They also speak with a caller with questions about a specific therapeutic for Covid and another caller who is looking to have Adam come out to a rally they are hosting in San Diego.”
Phase 3 FDA clinical trial at .44 cents.... what a gift. When the big boys get the news of this drug being approved there will be no chance to add anywhere close to this level, it will be 10x before market open.
Are those top asks even real? They’ve been looking fake all day...
Hard to put fear in people that own a phase 3 FDA ticker...
Everyone holds bags on the big runners. You should do some research before talking about pumping. This ticker ain’t the one...
Happy New Year to you as well!
It will definitely surpass the .72 mark. Millions and millions of shares were bought about .60. We are holding a huge winner. Just have to weather the storms of short term holders on the way up like always. The truly huge runners always pull back along the way. It’s healthy....
Hoping for an end of day/year surge off of this support level in anticipation of that good news that’s on the way.
Further to the DSMB review and recommendations on the interim analysis periods, the Company aims to file for an Emergency Use Authorization (“EUA”) of Bucillamine for mild to moderate COVID-19 with the FDA.
I guess he doesn’t realize we have access to his posting history. It’s just annoying...
So the CEO is a liar now? If you don’t like this company then go pound sand somewhere else. Sick of your bitchin.....
Interesting to see Revive in this group of large global firms.
It’s interesting to see how the mm’s get the “not so bright” to sell them shares at this level...
Mm’s having a field day with this low volume. Nearly 100mil shares traded above .50 in the last several trading sessions.
Lol, didn’t know you were there... just watching people chase volume surges the last few days. It will come here on FDA news. Looking forward to our 120mil volume days ahead.
People too busy chasing battery company and billion share OS junk. We are good here... lots to look forward to.
Same thing happened yesterday morning at 8:00am....
What’s up with the 9200 shares showing on the chart between .6009 and .429 this morning.
Lol.... good read
These are big hints for what’s coming....
Correct...
EUA going to be filed...